PetVivo Reports Third Quarter of Fiscal 2024 Financial Results
EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).
- Conference call begins at 4:00 p.m. Central time today
EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”). - “We are excited about the progress the Company has made this past quarter, including the addition of Covetrus North America, LLC.
- (Covetrus), to distribute our products beginning in January 2024,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
- Cost of sales were $183,087 and $223,687 for the three months ended December 31, 2023 and 2022, respectively.